|
answer text |
<p>The National Institute for Health and Care Excellence (NICE) is the independent
body responsible for developing evidence-based guidance on whether new licensed medicines
should be routinely funded by the National Health Service, based on an assessment
of their costs and benefits.</p><p>The NICE published guidance in 2021 and 2023 recommending
Enhertu (trastuzumab deruxtecan) for the treatment of NHS patients with HER2-positive
breast cancer through the Cancer Drugs Fund, and it is now available to eligible NHS
patients in line with the NICE’s recommendations.</p><p>The NICE is currently evaluating
Enhertu for the treatment of metastatic HER2-low breast cancer, and published final
draft guidance on 5 March 2024 that does not recommend it as a clinically and cost-effective
use of NHS resources. Stakeholders have until 19 March 2024 to lodge an appeal against
the NICE’s recommendations. The NICE currently expects to publish final guidance on
3 April 2024.</p>
|
|